Login to Your Account



Clinic Roundup


Thursday, March 22, 2012
• Addex Therapeutics SA, of Geneva, reported top-line data showing that a Phase IIa trial testing dipraglurant, a small-molecule allosteric modulator, in Parkinson's disease patients suffering from debilitating levodopa-induced dyskinesia (LID) met its primary endpoint, with the drug exhibiting a good safety and tolerability profile.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription